American Cannabis Company Announces Its Maryland Client Was Awarded An Operational License For The States Marijuana Dispensary Program
- December 20, 2016
- Posted by: Terry Buffalo
- Category: Consulting Services, Economics
DENVER, CO / NEW MEDIA NEWS / December 20, 2016 / American Cannabis Company, Inc. (OTCQB: AMMJ) (the “Company”), a full-service business-to-business consulting solutions provider, and seller of ancillary products to the cannabis industry, today announced its Maryland based client successfully secured a dispensary license for the state’s new medical cannabis program. This authorization allows the client to distribute cannabis to qualifying patients within the state of Maryland.
Corey Hollister, CEO of American Cannabis Company, commented: “We are excited about our client securing a license to operate in this emerging market. Maryland has done a strong job structuring the market and positioning operators for success in meeting the needs of qualifying patients within the state.”
About American Cannabis Company, Inc.:
American Cannabis Company, Inc. offers end-to-end solutions to existing and aspiring participants in the cannabis industry. We utilize our industry expertise to provide business planning and market assessment services, assist state licensing procurement, create business infrastructure and implement operational best practices. American Cannabis Company also developed and owns a portfolio of branded products including: The patented Satchel™, SoHum Living Soils™, The Cultivation Cube™ and The High Density Cultivation System™. In addition, we design and provide other industry specific custom product solutions. The building and development of our brands and product suite is based on our Geoponics Philosophy, “the art and science of agriculture in soil.”
For more information, please visit:
Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.
Chief Operating Officer